U.S. Markets open in 7 hrs 28 mins

Free Research Report as Novartis’ Sales Jumped 10% and Core EPS Advanced 13%

Stock Monitor: Sanofi Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free earnings report on Novartis AG (NYSE: NVS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NVS. The Company reported its first quarter fiscal 2018 operating and financial results on April 19, 2018. The Basel-based drug maker topped revenue estimates. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Sanofi (NYSE: SNY), which also belongs to the Healthcare sector as the Company Novartis. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=SNY

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Novartis AG most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=NVS

Earnings Highlights and Summary

For the first quarter of the fiscal year 2018, Novartis recorded net sales of $12.7 billion, up 10% compared to $11.5 billion in Q1 2017, as a volume growth of 9% was partly offset by the negative impacts of pricing (-3%) and generic competition (-2%). The Company's revenue numbers topped analysts' estimates of $12.6 billion.

During Q1 2018, Novartis' operating income surged 27% to $2.4 billion compared to $1.9 billion in Q1 2017, primarily driven by higher sales and lower net impairment charges, partly offset by higher growth investments. The Company's core operating income of $3.3 billion was 11% higher on a y-o-y basis.

Novartis reported a net income of $2.0 billion, or $0.87 per share, compared to $1.7 billion, or $0.70 per share, in Q1 2017, driven by the strong operating income and lower number of shares outstanding, partly offset by the lower income from associated companies.

For Q1 2018, Novartis' core earnings per share (EPS) advanced 13% to $1.28 compared to $1.13 in Q1 2017, driven by a growth in core net income and the lower number of shares outstanding. The Company's EPS lagged Wall Street's estimates of $1.29.

Segment Results

During Q1 2018, Novartis' Innovative Medicines Group generated net sales of $8.4 billion, up 12% compared to $7.5 billion in Q1 2017. The Company's volume contributed 11% to the segment's sales growth in the reported quarter, the highest quarterly volume growth in the last two years. Generic competition had a negative impact of 3%, while pricing had a negative impact of 2%. For Q1 2018, the segment's operating income surged 27% to $2.1 billion on a y-o-y basis, mainly driven by higher sales and lower net impairment charges, but partly offset by generic erosion and growth investments, and the China field force expansion.

During Q1 2018, Novartis' Sandoz segment's net sales grew 4% to $2.5 billion compared to $2.4 billion in Q1 2017, as a 6% of price erosion, mainly in the US, was partly offset by a volume growth of 2%. The segment's operating income advanced 19% to $409 million on a y-o-y basis, primarily driven by the continued gross margin improvement and gains from the divestment of non-strategic assets.

During Q1 2018, Novartis' Alcon segment's net sales totaled $1.8 billion, up 12% compared to $1.6 billion in Q1 2017, with growth in all product categories. The segment's stock-in-trade movements accounted for approximately 1% of growth. Alcon's strong results reflected the benefits from improved operations, customer relationships, and product launches. The segment had an operating income of $90 million in the reported quarter compared to a loss of $2 million in the prior year's same quarter, largely driven by higher sales.

Cash Matters

As of March 31, 2018, Novartis' liquidity amounted to $6.4 billion compared to $9.5 billion at December 31, 2017, and the total of the non-current and current financial debt, including derivatives, amounted to $34.1 billion at March 31, 2018, compared to $28.5 billion at December 31, 2017.

At March 31, 2018, Novartis' net debt increased to $27.7 billion compared to $19.0 billion at December 31, 2017. The Company's debt to equity ratio increased to 0.48:1 at March 31, 2018, compared to 0.38:1 at December 31, 2017.

During Q1 2018, Novartis' cash flows from operating activities amounted to $2.5 billion compared to $2.0 billion in Q1 2017. The increase of $0.5 billion was mainly driven by a higher net income adjusted for non-cash items, as well as favorable working capital changes due to the receipt of a sales milestone recognized in Q4 2017, related to the Vaccines divestment to GSK.

For Q1 2018, Novartis' free cash flow amounted to $1.9 billion compared to $1.7 billion in the prior year's corresponding quarter, mainly driven by higher cash flows from operating activities, and partly offset by higher investments in intangible assets.

Stock Performance Snapshot

May 02, 2018 - At Wednesday's closing bell, Novartis' stock slightly dropped 0.64%, ending the trading session at $75.79.

Volume traded for the day: 1.61 million shares.

After yesterday's close, Novartis' market cap was at $196.44 billion.

Price to Earnings (P/E) ratio was at 22.35.

The stock has a dividend yield of 3.93%.

The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors